Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.

Eur Heart J · 2025 · PMC12011522 · PMID 39907687

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

without anaemia ( P interaction < .100 for all measures, including a nominally significant P interaction = .022 for the decrease in LV end-systolic volume).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.